Objectives: Primary objective was to determine in daily routine if the use of Contour® Next One (CNO) with Smartphone Application Contour® Diabetes app (CDA) was associated with improved self-management by means of the Summary of Diabetes Self-Care Activities questionnaire (SDSCA). Secondary objectives were to evaluate impact on adherence to self-monitoring blood glucose (BG), change in HbA1c, quality of life and patient empowerment.

Material and Methods: Prospective, observational study in 9 clinical practices in Spain. Eighty-seven multiple dose Insulin-treated patients with either type 1 or 2 diabetes mellitus were enrolled. All patients were using the CNO without the CDA, had a recent HbA1c test and previous 3 month glucose data. Each one had 2 on site visits at 0 days (visit 1) and 90 (visit 2).

Results: Eighty-four patients were eligible (88.1% type 1; 11.9% type 2). Statistical significant differences were observed in SDSCA for general and specific diet questions with an increase of 1 day of median between visits. A significant increase was found in the number of total BG readings [median 259.1 vs. 276.1] and BG readings per day [median 2.9 vs. 3.1]. Furthermore, the % of BG values in range was significantly increased in visit 2 [median 51.0% vs. 54.0%] and the average of BG values decreased [median 169.0 vs. 161.5 mg/dl ]. Consequently a significant decrease in HbA1c value was observed [mean 7.6% vs. 7.38%]. No significant differences were found on the scores of the quality of life and empowerment questionnaires.

Conclusion: These results suggest that the addition of the smartphone CDA to CNO in daily routine does not reduce the quality of life or empowerment of patients with diabetes but instead their joint use allows them to achieve a better glycemic control within a short period of time. This improvement seems to be obtained by following more days a healthier diet and by greater adherence to self-monitoring.


D. Fernandez-Garcia: Consultant; Self; Abbott, AstraZeneca, LifeScan, Inc., Lilly Diabetes, Madaus, Menarini Group, MSD, Novartis AG, Novo Nordisk A/S, Roche Diabetes Care, Sanofi. Other Relationship; Self; Ascensia Diabetes Care, Pfizer Inc., Sanofi. E. Aguilera: None. J. Arranz Martín: None. B. Gonzalez: None. B.G. Jauregui: None. E. Menéndez-Torre: None. R. Reyes-Garcia: None. A. Soto Gonzalez: Advisory Panel; Self; Novartis, Novo Nordisk. Consultant; Self; Mundipharma International, Novartis, Novo Nordisk. Speaker’s Bureau; Self; Eli Lilly and Company, Janssen/Mundipharma, Novartis, Novo Nordisk, Sanofi. C. Tejera: None. B. Fernandez-Tresguerres Torrecillas: Employee; Self; Ascensia Diabetes Care. T. Petruschke: Employee; Self; Ascensia Diabetes Care.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.